Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358289 | 1.00 | GAA (0.38) | GAAMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL22275674 | 0.80 | ESR2 (0.40) | MAPTKDM4EHPGDKMT2ACYP19A1 | |
| SCHEMBL9051041 | 0.80 | SLC6A2 (0.44) | GAAMAPTKDM4EALDH1A1HPGD | |
| Oxazolidine SCHEMBL14720881 | 0.73 | SLC6A2 (0.36) | GAAKDM4EALDH1A1PRCPGID4 | |
| SCHEMBL15111039 | 0.72 | SLC6A2 (0.38) | GAAKDM4EALDH1A1CA2PRCP | |
| SCHEMBL28370024 | 0.72 | MEN1 (0.50) | GAAMAPTKMT2ACYP19A1LMNA | |
| Formaldehyde SCHEMBL28641500 | 0.72 | MEN1 (0.46) | GAAMAPTKDM4EALDH1A1KMT2A | |
| Methane SCHEMBL28643467 | 0.71 | MEN1 (0.49) | GAAMAPTKMT2ACYP19A1LMNA | |
| SCHEMBL8664410 | 0.69 | HDAC8 (0.54) | MAPTALDH1A1PRCP | |
| SCHEMBL9735953 | 0.68 | CHRNB2 (0.41) | KMT2ACA2LMNAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1150951-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000040553-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | MMP3, MMP1, MMP9 | GAA 210/4885MAPT 3351/4885KDM4E 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.